| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 26.06 | 0.7% | 604.3% |
| Total Income | 26.06 | 0.7% | 604.3% |
| Expenditure | 20.37 | 15.9% | 25.0% |
| PBT | -0.98 | 101.3% | 97.0% |
| Net Profit | -0.54 | 100.7% | 98.4% |
| OPM | 15.90% | ||
| NPM | -2.09% | 102.09pp | |
| EPS | -0.01 | 100.8% | 98.5% |
Zevra Therapeutics Reports Q3 2025 Financial Results
04 May 2026 · 4 May, 8:03 am
Summary
The press release announces Zevra Therapeutics' financial results and corporate updates for the third quarter ended September 30, 2025. It also mentions a conference call and audio webcast to discuss these results and updates, scheduled for November 5, 2025.
Informational and educational content only. Not investment advice.